U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics ' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer

SAN DIEGO, Feb. 15, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for adagrasib for...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news